Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$100,0000%Beat EPS +8,355.3%
Total revenue, Q2 '24 ().

Did Inhibrx Biosciences Beat Earnings?

Inhibrx Biosciences (INBX) reported Q2 '24 revenue of $100,000, with reported EPS of $125.48. That topped the $-1.52 analyst estimate by 8,355.3% — an earnings beat.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Inhibrx Biosciences’s job postings, web traffic, and employee business outlook. See the full INBX stock analysis or the earnings calendar for upcoming reports.

Inhibrx Biosciences Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue—100,000—1.3M————
Gross margin—-589.0%—49.1%————
Operating margin—-49,928.0%—-2,106.8%————
Net income-44M-48M-43M-29M-35M-33M-33M-37M
Net margin—-47,865.0%—-2,204.2%————
EPS————————

Inhibrx Biosciences Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Inhibrx Biosciences’s quarterly revenue moved from $0 to $0. Inhibrx Biosciences has beaten Wall Street EPS estimates in 1 of its last 1 reported quarters.

When Is Inhibrx Biosciences’s Next Earnings Date?

Inhibrx Biosciences reports earnings on a quarterly schedule. Its most recent report covered Q2 '24. For the confirmed upcoming date — and every other company reporting soon — see the INBX earnings calendar.

Frequently Asked Questions: Inhibrx Biosciences Earnings

Inhibrx Biosciences's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Inhibrx Biosciences reported Q2 '24 EPS of $125.48 on revenue of $100,000. Inhibrx Biosciences beat estimates, reporting $125.48 vs. the $-1.52 estimate.

Inhibrx Biosciences reported Q2 '24 revenue of $100,000.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the INBX AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.